EUVIMEDEUVIMED entdecken
Crossref

The Five-Year Incidence of Progression to Osteoarthritis and Total Joint Arthroplasty in Patients Prescribed Glucagon-Like Peptide 1 Receptor Agonists

Monish S Lavu, Joshua R Porto, Christian J Hecht, David C Kaelber, Peter K Sculco, Nathanael D Heckmann, Atul F Kamath

The Journal of Arthroplasty · 2024-10 · 39 (10) · 2433-2439.e1

DOI: 10.1016/j.arth.2024.06.008 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Arthroplasty, 2024-10. Verfasst von Monish S Lavu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopaedics, Case Western Reserve University School of Medicine, Cleveland, Ohio; Department of Orthopaedic Surgery, Cleveland Clinic …. Hauptthemen laut MEDLINE: Arthroplasty, Replacement, Hip, Arthroplasty, Replacement, Knee, Obesity, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: National Institutes of Health, National Center for Advancing Translational Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Research has suggested that glucagon-like peptide-1 receptor agonists (GLP-1-RAs) may have therapeutic effects on osteoarthritis of the hip and knee, in addition to managing diabetes and obesity. However, there is a lack of understanding regarding the association between GLP-1-RA use and the diagnosis of osteoarthritis (OA) of the hip and knee. METHODS: A collaborative network analytics platform was queried for obese diabetic (n = 1,094,198), obese nondiabetic (n = 916,235), and nonobese diabetic (n = 157,305) patients who had an index visit between 2015 and 2017. Patients who had pre-existing hip and/or knee OA were excluded. A 1:1 propensity score matching was used to balance GLP-1-RA use in stratified cohorts for age, sex, race, body mass index, and hemoglobin A1c. The primary outcomes were rates of progression to hip OA, knee OA, major joint injections, total hip arthroplasty, and total knee arthroplasty. Cox proportional hazards models determined hazard ratios (HRs) between cohorts prescribed and not prescribed GLP-1-RAs. RESULTS: All patients had a five-year follow-up. Rates of progression to hip and knee OA were higher among the GLP-1-RA users in both obese diabetic (hip HR: 1.63, 95% confidence interval [CI]: 1.46 to 1.82; knee HR: 1.52, CI: 1.41 to 1.64) and nonobese diabetic (hip HR: 1.78, CI: 1.50 to 2.10; knee HR: 1.58, CI: 1.39 to 1.80) cohorts. These diabetic cohorts received higher rates of major joint injections, though there was no difference in rates of total hip arthroplasty or total knee arthroplasty. No differences in five-year outcomes were seen when comparing obese, nondiabetic patients who were prescribed GLP-1-RAs with obese, nondiabetic patients not exposed to GLP-1-RAs. CONCLUSIONS: This five-year analysis found a greater risk of progression to hip and knee OA among obese and non-obese diabetic GLP-1-RA users. Further studies should explore GLP-1-RA effects upon glucose management, weight loss, and lower extremity arthritis development. LEVEL OF EVIDENCE: III, retrospective cohort study.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthroplasty, Replacement, HipArthroplasty, Replacement, KneeObesityGlucagon-Like Peptide-1 Receptor AgonistsAgedFemaleHumansMaleMiddle AgedDiabetes Mellitus, Type 2Disease ProgressionHypoglycemic AgentsIncidenceOsteoarthritis, HipOsteoarthritis, KneeRetrospective Studies

Stichwörter der Autor:innen

diabetesglucagon-like peptide 1 (GLP-1) receptor agonistsosteoarthritistotal joint arthroplastyweight loss

Substanzen

Hypoglycemic AgentsGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Department of Orthopaedics, Case Western Reserve University School of Medicine, Cleveland, Ohio; Department of Orthopaedic Surgery, Cleveland Clinic Foundation, Cleveland, Ohio.
  • Departments of Internal Medicine, Pediatrics, and Population and Quantitative Health Sciences, Case Western Reserve University, Cleveland, Ohio; The Center for Clinical Informatics Research and Education, The MetroHealt…
  • Department of Orthopedics, Hospital for Special Surgery, New York, New York.
  • Department of Orthopaedic Surgery, Keck School of Medicine of USC, Los Angeles, California.
  • Department of Orthopaedic Surgery, Cleveland Clinic Foundation, Cleveland, Ohio.

Förderung

  • National Institutes of Health
  • National Center for Advancing Translational Sciences

Zitieren

APA

Lavu, M. S., Porto, J. R., Hecht, C. J., Kaelber, D. C., Sculco, P. K., Heckmann, N. D., & Kamath, A. F. (2024). The Five-Year Incidence of Progression to Osteoarthritis and Total Joint Arthroplasty in Patients Prescribed Glucagon-Like Peptide 1 Receptor Agonists. The Journal of Arthroplasty, 39(10), 2433-2439.e1. https://doi.org/10.1016/j.arth.2024.06.008

Vancouver

Lavu MS, Porto JR, Hecht CJ, Kaelber DC, Sculco PK, Heckmann ND, et al. The Five-Year Incidence of Progression to Osteoarthritis and Total Joint Arthroplasty in Patients Prescribed Glucagon-Like Peptide 1 Receptor Agonists. The Journal of Arthroplasty. 2024;39(10):2433-2439.e1. doi:10.1016/j.arth.2024.06.008

BibTeX
@article{Lavu2024,
  author = {Lavu, Monish S and Porto, Joshua R and Hecht, Christian J and Kaelber, David C and Sculco, Peter K and Heckmann, Nathanael D and Kamath, Atul F},
  title = {The Five-Year Incidence of Progression to Osteoarthritis and Total Joint Arthroplasty in Patients Prescribed Glucagon-Like Peptide 1 Receptor Agonists},
  journal = {The Journal of Arthroplasty},
  year = {2024},
  volume = {39},
  number = {10},
  pages = {2433--2439.e1},
  doi = {10.1016/j.arth.2024.06.008}
}
Kostenlos starten →